@article{Hughes_E-2020_6008,
title = {SARS-CoV-2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting},
author = {Hughes, E. and Amat, J. and Haney, J. and Parr, Y. and Logan, N. and Palmateer, N. and Nickbakhsh, S. and Ho, A. and Cherepanov, P. and Rosa, A. and McAuley, A. and Broos, A. and Herbert, I. and Arthur, U. and Szemiel, A. and Roustan, C. and Dickson, E. and Gunson, R. and Viana, M. and Willett, B. and Murcia, P.},
month = {dec},
year = {2020},
abstract = {Identifying drivers of SARS-CoV-2 exposure and quantifying population immunity is crucial to prepare for future epidemics. We performed a serial cross-sectional serosurvey throughout the first pandemic wave among patients from the largest health board in Scotland. Screening of 7480 patient sera showed a weekly seroprevalence ranging from 0.10% to 8.23% in primary and 0.21% to 17.44% in secondary care, respectively. Neutralisation assays showed that around half of individuals who tested positive by ELISA assay, developed highly neutralising antibodies, mainly among secondary care patients. We estimated the individual probability of SARS-CoV-2 exposure and quantified associated risk factors. We show that secondary care patients, males and 45-64-year-olds exhibit a higher probability of being seropositive. The identification of risk factors and the differences in virus neutralisation activity between patient populations provided insights into the patterns of virus exposure during the first pandemic wave and shed light on what to expect in future waves.},
pages = {971-980},
volume = {223},
issue = {6},
journal = {Journal of Infectious Diseases},
publisher = {Oxford University Press},
url = {https://doi.org/10.1093/infdis/jiaa788},
}
